BRAF and colorectal carcinoma: Approximately 5–9% of CRC patients carry BRAF V600E allele mutations, and multiple studies suggest that mutations in BRAF V600E can lead to the activation of persistent downstream signaling pathways leading to cell proliferation or survival and suggesting poor prognosis (Guedes et al., 2013; Li et al., 2013).